文献速递神经免疫

脊髓体积loss:多发性硬化疾病进展的标志物

Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
PubMed 文献 · Neurology · 2018-06-27

本研究对231例复发起病型多发性硬化患者(180例复发缓解型、51例继发进展型)进行6年每年随访,测量上颈段脊髓体积、全脑体积和脑T2病灶体积。结果显示脊髓体积loss可预测残疾进展,每年脊髓体积loss率每增加1%与随后一年疾病进展风险增加28%相关。

要点

  • 继发进展型患者基线脊髓体积较低,但脊髓体积loss速度与复发缓解型无差异。
  • 复发缓解型中临床复发可预测脊髓体积loss。
  • 脊髓体积loss(而非全脑体积或T2病灶体积)可预测EDSS评分恶化。

核心结论

  • 脊髓体积loss与复发缓解型患者的临床复发次数相关,但复发缓解型与继发进展型之间总体无差异。
  • 脊髓体积被证明是躯体残疾和疾病进展的强预测指标,可能适合作为监测疾病活动和严重程度的标志物。

研究设计与样本

  • 对231例复发起病型多发性硬化患者(180例复发缓解型、51例继发进展型)进行为期6年的每年随访,采集三维T1加权磁化准备快速采集梯度回波图像。
  • 每年测量上颈段脊髓体积、全脑体积和脑T2病灶体积,并在每次随访时记录EDSS评分和复发情况。

主要发现

  • 继发进展型患者基线脊髓体积低于复发缓解型(p < 0.01),但脊髓体积loss速度未加速。
  • 复发缓解型中临床复发可预测随时间发生的脊髓体积loss(p < 0.05)。
  • 脊髓体积loss(而非全脑体积和T2病灶体积)是随时间EDSS评分恶化的强预测指标(p < 0.05)。
  • 年均脊髓体积loss率是复发缓解型和继发进展型各自年均EDSS评分变化的最强MRI预测指标,且在继发进展型中相关性更强。
  • 两组中每年脊髓体积loss率每增加1%,与随后一年疾病进展风险增加28%相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cross-sectional studies have shown that spinal cord volume (SCV) loss is related to disease severity in multiple sclerosis (MS). However, long-term data are lacking. Our aim was to evaluate SCV loss as a biomarker of disease progression in comparison to other MRI measurements in a large cohort of patients with relapse-onset MS with 6-year follow-up. METHODS: The upper cervical SCV, the total brain volume, and the brain T2 lesion volume were measured annually in 231 patients with MS (180 relapsing-remitting [RRMS] and 51 secondary progressive [SPMS]) over 6 years on 3-dimensional, T1-weighted, magnetization-prepared rapid-acquisition gradient echo images. Expanded Disability Status Scale (EDSS) score and relapses were recorded at every follow-up. RESULTS: Patients with SPMS had lower baseline SCV (p < 0.01) but no accelerated SCV loss compared to those with RRMS. Clinical relapses were found to predict SCV loss over time (p < 0.05) in RRMS. Furthermore, SCV loss, but not total brain volume and T2 lesion volume, was a strong predictor of EDSS score worsening over time (p < 0.05). The mean annual rate of SCV loss was the strongest MRI predictor for the mean annual EDSS score change of both RRMS and SPMS separately, while correlating stronger in SPMS. Every 1% increase of the annual SCV loss rate was associated with an extra 28% risk increase of disease progression in the following year in both groups. CONCLUSION: SCV loss over time relates to the number of clinical relapses in RRMS, but overall does not differ between RRMS and SPMS. SCV proved to be a strong predictor of physical disability and disease progression, indicating that SCV may be a suitable marker for monitoring disease activity and severity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tsagkas C, Magon S, Gaetano L, et al. Spinal cord volume loss: A marker of disease progression in multiple sclerosis. Neurology. 2018. PMID: 29950437. doi:10.1212/WNL.0000000000005853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。